{"store":{"baseInfo":{"podcastTitle":"The Pharm So Hard Emergency Medicine & Hospital Pharmacy Podcast","slug":"jimmyrq","podcastDescription":"The Pharm So Hard Podcast is a show focused primarily on emergency medicine and hospital pharmacy related topics. Episodes range from 5-30 minutes depending on the topic and guest speakers. The goal is to disseminate information in bite-sized episodes from experts in the field of acute care and hospital pharmacy sub-specialties.","podcastLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/18130768/avatars-000688425426-5pwyrm-original.jpg","podcastShareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/18130768/avatars-000688425426-5pwyrm-original_1200x628.jpg?s=26f3c6fa0fae4490783a216d4691f8f8&e=jpg","podcastUrl":"https://jimmyrq.podbean.com","podcastCanSearched":true,"feedUrl":"https://feed.podbean.com/jimmyrq/feed.xml","theme":"elegant","podcastDeepLink":"https://www.podbean.com/pw/pbblog-j9fca-114a750?from=usersite","removePodbeanBranding":"yes","brandingLogo":"http://imglogo.podbean.com/companyLogo/18136751/2024-03-13_113402e53bf7d7-0d9c-2893-4d93-ca2ba83dd560_y88er.jpg","timeZone":{"timeZoneId":15,"gmtAdjustment":"GMT-05:00","useDaylightTime":1,"value":-5,"text":"(GMT-05:00) Eastern Time (US & Canada)","daylightStartTime":"Second Sunday Of March +2 Hours","daylightEndTime":"First Sunday Of November +2 Hours","timezone":"America/New_York"},"podcastDownloads":null,"totalEpisodes":125,"showComments":true,"iOSAppDownloadLink":null,"customizeCssUrl":null,"androidAppDownloadLink":null,"showPostShare":true,"showLike":false,"author":"Jimmy Pruitt, PharmD, BCPS, BCCCP, BCEMP","enableEngagementStats":true,"shareEmbedLink":"https://admin5.podbean.com/embed.html?id=pbblog-j9fca-114a750-playlist","language":"en","sensitivitySessionExpireTime":3600,"podcastApps":[{"name":"Apple Podcasts","link":"https://podcasts.apple.com/us/podcast/the-pharm-so-hard-podcast-an-emergency-medicine-and-hospital-pharmacy-podcast/id1479624416","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/apple-podcast.png","title":null},{"name":"Podbean App","link":"https://www.podbean.com/pw/pbblog-j9fca-114a750?from=usersite","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/podbean-app.png","title":null},{"name":"Spotify","link":"https://open.spotify.com/show/367btSv26kqQ2Ra1RA09mf","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/spotify.png","title":null}],"components":{"base":[{"id":"MainStyle","val":"light"},{"id":"Font","val":"Avenir"},{"id":"SecondaryFont","val":"Avenir"},{"id":"PlayerColor","val":"#8fc31f"},{"id":"PlayerStyle","val":"player1"},{"id":"PlayerWave","val":"show"},{"id":"Favicon","val":null},{"id":"CookiesNotice","val":"hide"},{"id":"CookiesNoticeContent","val":"

Cookies Notice

This website uses cookies to improve your experience while you navigate through the website. By using our website you agree to our use of cookies.

"}],"home-header":[{"id":"HomeHeaderTextColor","val":"#000000"},{"id":"HomeHeaderBackgroundColor","val":"#ffffff"}],"page-header":[{"id":"PageHeaderTextColor","val":"#ffffff"},{"id":"PageHeaderBackgroundColor","val":"#868686"}],"episode-list":[{"id":"EpisodeListType","val":"grid"},{"id":"EpisodesPerPage","val":10},{"id":"EpisodeStats","val":"show"}],"navigation":[{"id":"NavigationFontColor","val":"#000000"},{"id":"NavigationBackgroundColor","val":"#e9e9e9"},{"id":"NavigationSearch","val":"show"},{"id":"NavigationLinks","val":[{"id":"Home","type":"Link","value":"/","text":"Home","subitems":[]},{"id":"Subscribe","type":"Link","value":"https://www.podbean.com/site/podcatcher/index/blog/KkWyqbhYAfpw","text":"Subscribe","subitems":[]},{"id":"Profile","type":"Link","value":"https://www.podbean.com/user-GNW7m1SMGSe7","text":"Profile","subitems":[]}]}],"footer":[{"id":"FooterType","val":"Footer2"},{"id":"FooterFontColor","val":"#ffffff"},{"id":"FooterBackgroundColor","val":"#000000"},{"id":"FooterCopyright","val":"All rights reserved"},{"id":"SocialMediaLinks","val":{"facebook_username":"","twitter_username":"","instagram_username":"","youtube_username":"","linkedin_username":""}}],"customize-container1":[],"customize-container2":[{"id":"ComponentImageText-1","val":{"ComponentFontColor":"#000000","ComponentBackgroundColor":"#f2f2f2","ComponentImage":"https://mcdn.podbean.com/mf/web/j2pwxh/PharmSoHard_Logo-037a54f9f3-7a34-aaf5-ebc0-4d9423e18164.png","ComponentContent":"

Pharm So Hard Podcast

The Pharm So Hard Podcast is a show focused primarily on emergency medicine and hospital pharmacy related topics. Episodes range from 5-30 minutes depending on the topic and guest speakers. The goal is to disseminate information in bite-sized episodes from experts in the field of acute care and hospital pharmacy sub-specialties.

"}}]},"allLinks":[],"mainStylesDefaultSettings":null,"defaultCustomizeComponents":null,"scripts":[],"metas":null,"appConfig":{"package":"com.podbean.app.generic","app_store_id":1484287462,"app_name":"Podbean Biz Podcast App","scheme":"enterprise-podbean-com"},"customizeCss":null,"canEditCss":null,"enableJsCodeInCustomizeContent":false,"enabledIframeCodeInCustomizeContent":true,"sectionMaxCount":10,"enableEditorLink":true,"enableEditCookiesNotice":true,"siteRedirectToFeed":false,"podcatcherRssUrl":null,"showFeed":true,"showTopBar":true,"enableWebSiteLike":false,"organizationName":"Pharm So Hard Network","organizationPageLink":"https://www.podbean.com/podcast-network/jimmyrqj2rytqmm"},"backToListUrl":"/","tinymceLoaded":false,"listEpisodes":[],"userLikedEpisodes":[],"userLikeCheckedEpisodes":[],"topBarIframeLoaded":false,"listTotalCount":0,"listTotalPage":0,"listPage":0,"listType":"all","listValue":"","listName":"","pageLoading":false,"apiBaseUrl":"https://jimmyrq.podbean.com","apiCommonParams":{"t":"6865dac5","clientSignature":"04331d047d08a6fdae734fdaf5815f55","u":null,"customizing":null},"apiCommonHeaders":{},"comments":[],"commentsTotalCount":0,"commentsTotalPage":0,"commentsPage":1,"commentEpisodeId":"pb22566162-5guqc","episode":{"id":"pb22566162","idTag":"5guqc","title":"Episode 102. The Controversy of Cefdinir in UTIs","logo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a_1200x628.jpg?s=897bba2e02c76128792becd4f04adf53&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a.jpg","previewContent":null,"content":"In this episode of the Pharm So Hard Podcast, Jimmy L. Pruitt III, PharmD, BCPS, BCCCP talks about whether or not Cefdinir is good for UTI.","publishTimestamp":1686614040,"duration":1118,"mediaUrl":"https://mcdn.podbean.com/mf/web/8p719b/e_http___feeds_soundcloud_com_stream_1538134177-pharmsohard-the-controversy-of-cefdinir-in-utis.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-5guqc-1585512","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-5guqc-1585512","transcriptUrl":null,"permalink":"/e/episode-102-the-controversy-of-cefdinir-in-utis/","downloadLink":"https://www.podbean.com/media/share/pb-5guqc-1585512?download=1","fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":276,"status":"publish","hasMoreContent":false,"chaptersUrl":null,"explicit":false},"episodeShareLink":null,"deepLink":"https://www.podbean.com/ew/pb-5guqc-1585512","playlist":{"episodes":[],"current":0,"start":0,"stop":0,"playing":true,"playerLoading":true,"playbackRate":1,"playbackRateIndex":1},"toasts":[],"confirm":null,"customizeEditorFormZIndex":999,"lastRequestTime":null,"validateChangesOnBeforeunload":true,"windowWidth":1000,"VITE_FS1_CDN_URL_PREFIX":"https://pbcdn1.podbean.com/fs1","reloadStats":false,"userIdEncrypted":null,"userProfilePicture":null,"username":null,"isVerified":false,"loadUserInfo":false,"loginUrl":"https://www.podbean.com/site/user/login?return=https%253A%252F%252Fjimmyrq.podbean.com%252Fe%252Fepisode-102-the-controversy-of-cefdinir-in-utis%252F&rts=c91f61f6e44816b9445812f224ff0050787bf224","recaptchaV3Loaded":false,"recaptchaV2Loaded":false,"likesLoaded":false,"commentLikeMap":{},"commentOffset":0},"episode":{"id":"pb22566162","idTag":"5guqc","title":"Episode 102. The Controversy of Cefdinir in UTIs","logo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a_1200x628.jpg?s=897bba2e02c76128792becd4f04adf53&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog18130768/b3e158f89bf110e0a9822ae7bf395a2a.jpg","previewContent":null,"content":"In this episode of the Pharm So Hard Podcast, Jimmy L. Pruitt III, PharmD, BCPS, BCCCP talks about whether or not Cefdinir is good for UTI.","publishTimestamp":1686614040,"duration":1118,"mediaUrl":"https://mcdn.podbean.com/mf/web/8p719b/e_http___feeds_soundcloud_com_stream_1538134177-pharmsohard-the-controversy-of-cefdinir-in-utis.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-5guqc-1585512","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-5guqc-1585512","transcriptUrl":null,"permalink":"/e/episode-102-the-controversy-of-cefdinir-in-utis/","downloadLink":"https://www.podbean.com/media/share/pb-5guqc-1585512?download=1","fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":276,"status":"publish","hasMoreContent":false,"chaptersUrl":null,"explicit":false},"loginUrl":"https://www.podbean.com/site/user/login?return=https%253A%252F%252Fjimmyrq.podbean.com%252Fe%252Fepisode-102-the-controversy-of-cefdinir-in-utis%252F&rts=c91f61f6e44816b9445812f224ff0050787bf224"}